Yahoo
HKSE - Delayed Quote HKD

MicroPort CardioFlow Medtech Corporation (2160.HK)

1.280 0.000 (0.00%)
At close: August 31 at 4:08:46 PM GMT+8

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
Name Title Pay Exercised Year Born
Mr. Guoming Chen
CEO & Executive Director -- -- 1985
Mr. Ruinian Zhang
President & Executive Director 1.8M -- 1964
Mr. Paul Vodden
Chief Financial Officer -- -- 1966
Mr. Xiaoming Zhu
Chief Operating Officer -- -- 1968
Ms. Alice Flacco
Executive VP & General Counsel -- -- 1985
Mr. Hugues Gervais
Chief Commercial Officer -- -- --
Ms. Xiangmei Li
Joint Company Secretary -- -- --
Ms. Lok Yee Chan A.C.I.S., A.C.S.
Joint Company Secretary -- -- 1990

MicroPort CardioFlow Medtech Corporation

No. 501 Niudun Road
Zhangjiang Hi-Tech Park Pudong New District
Shanghai
China
https://www.cardioflowmedtech.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
1,415

Description

MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilation catheter, Angelguide, an advanced pre-shaped ultra-hard guidewire; and AnchorMan, a left atrial appendage occlusion and guidance system. It also provides various active, mitral, and tricuspid valve products; left atrial appendage closure products; surgical accessories; low and high-voltage CRM products; leads and accessories; patient monitoring products; and arrhythmia diagnostic devices. In addition, the company offers clinical solutions, including aortic stenosis and atrial fibrillation-related stroke prevention. Further, it is involved in the manufacturing of raw materials for medical devices treating valvular heart diseases; and properties management. The company was founded in 2009 and is headquartered in Shanghai, China.

Corporate Governance

MicroPort CardioFlow Medtech Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: